Ancillary testing in lung cancer diagnosis

Pulmonary Medicine

Volumn , Issue , 2012, Pages

  Dubinski, William ^a,b   Leighl, Natasha B ^c   Tsao, Ming Sound ^a,b   Hwang, David M ^a,b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ASPARTIC PROTEINASE; BEVACIZUMAB; BIOLOGICAL MARKER; CRIZOTINIB; CYTOKERATIN; CYTOKERATIN 20; DOCETAXEL; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; K RAS PROTEIN; KI 67 ANTIGEN; NAPSIN A; PEMETREXED; PROTEIN; PROTEIN P53; SCATTER FACTOR RECEPTOR; THYROID TRANSCRIPTION FACTOR 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PROGNOSIS; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MOLECULAR DIAGNOSIS; NEUROENDOCRINE TUMOR; NONHUMAN; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 84863998436     PISSN: 20901836     EISSN: 20901844     Source Type: Journal    
DOI: 10.1155/2012/249082     Document Type: Review

References (56)

1. Travis W. D., Brambilla E., Muller-Hermelink H. K., Harris C. C., Pathology and Genetics of Tumours of the Lung, Pleura, Thymus, and Heart 2004 Lyon, France IARC World Health Organization Classification of Tumours
2. Travis W. D., Brambilla E., Noguchi M., Nicholson A. G., Geisinger K. R., Yatabe Y., Beer D. G., Powell C. A., Riely G. J., Van Schil P. E., Garg K., Austin J. H.M., Asamura H., Rusch V. W., Hirsch F. R., Scagliotti G., Mitsudomi T., Huber R. M., Ishikawa Y., Jett J., Sanchez-Cespedes M., Sculier J. -P., Takahashi T., Tsuboi M., Vansteenkiste J., Wistuba I., Yang P. -C., Aberle D., Brambilla C., Flieder D., Franklin W., Gazdar A., Gould M., Hasleton P., Henderson D., Johnson B., Johnson D., Kerr K., Kuriyama K., Lee J. S., Miller V. A., Petersen I., Roggli V., Rosell R., Saijo N., Thunnissen E., Tsao M., Yankelewitz D., International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma Journal of Thoracic Oncology 2011 6 2 244 285
3. Xu B., Thong N., Tan D., Khoury T., Expression of thyroid transcription factor-1 in colorectal carcinoma Applied Immunohistochemistry and Molecular Morphology 2010 18 3 244 249
4. Loo P. S., Thomas S. C., Nicolson M. C., Fyfe M. N., Kerr K. M., Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens Journal of Thoracic Oncology 2010 5 4 442 447
5. Nicholson A. G., Gonzalez D., Shah P., Pynegar M. J., Deshmukh M., Rice A., Popat S., Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of Mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis Journal of Thoracic Oncology 2010 5 4 436 441
6. Ye J., Findeis-Hosey J. J., Yang Q., McMahon L. A., Yao J. L., Li F., Xu H., Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung Applied Immunohistochemistry and Molecular Morphology 2011 19 4 313 317
7. Monica V., Ceppi P., Righi L., Tavaglione V., Volante M., Pelosi G., Scagliotti G. V., Papotti M., Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung Modern Pathology 2009 22 5 709 717
8. Schweizer J., Bowden P. E., Coulombe P. A., Langbein L., Lane E. B., Magin T. M., Maltais L., Omary M. B., Parry D. A. D., Rogers M. A., Wright M. W., New consensus nomenclature for mammalian keratins Journal of Cell Biology 2006 174 2 169 174 (Pubitemid 44079852)
9. Boggaram V., Thyroid transcription factor-I (TTF-I/Nkx2.I/TITFI) gene regulation in the lung Clinical Science 2009 116 1 27 35
10. Johnson D. H., Fehrenbacher L., Novotny W. F., Herbst R. S., Nemunaitis J. J., Jablons D. M., Langer C. J., DeVore R. F., Gaudreault J., Damico L. A., Holmgren E., Kabbinavar F., Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer Journal of Clinical Oncology 2004 22 11 2184 2191 (Pubitemid 41095154)
11. Sandler A. B., Schiller J. H., Gray R., Dimery I., Brahmer J., Samant M., Wang L. I., Johnson D. H., Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab Journal of Clinical Oncology 2009 27 9 1405 1412
12. Socinski M. A., Novello S., Brahmer J. R., Rosell R., Sanchez J. M., Belani C. P., Govindan R., Atkins J. N., Gillenwater H. H., Pallares C., Tye L., Selaru P., Chao R. C., Scagliotti G. V., Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer Journal of Clinical Oncology 2008 26 4 650 656 (Pubitemid 351264362)
13. Scagliotti G. V., Parikh P., Von Pawel J., Biesma B., Vansteenkiste J., Manegold C., Serwatowski P., Gatzemeier U., Digumarti R., Zukin M., Lee J. S., Mellemgaard A., Park K., Patil S., Rolski J., Goksel T., De Marinis F., Simms L., Sugarman K. P., Gandara D., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer Journal of Clinical Oncology 2008 26 21 3543 3551
14. Ciuleanu T., Brodowicz T., Zielinski C., Kim J. H., Krzakowski M., Laack E., Wu Y. L., Bover I., Begbie S., Tzekova V., Cucevic B., Pereira J. R., Yang S. H., Madhavan J., Sugarman K. P., Peterson P., John W. J., Krejcy K., Belani C. P., Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study The Lancet 2009 374 9699 1432 1440
15. Yatabe Y., Mitsudomi T., Takahashi T., TTF-1 expression in pulmonary adenocarcinomas American Journal of Surgical Pathology 2002 26 6 767 773 (Pubitemid 34546942)
16. Fatima N., Cohen C., Lawson D., Siddiqui M. T., TTF-1 and Napsin A double stain: a useful marker for diagnosing lung adenocarcinoma on fine-needle aspiration cell blocks Cancer Cytopathology 2011 119 2 127 133
17. Lim E., Goldstraw P., Nicholson A. G., Travis W. D., Jett J. R., Ferolla P., Bomanji J., Rusch V. W., Asamura H., Skogseid B., Baudin E., Caplin M., Kwekkeboom D., Brambilla E., Crowley J., Proceedings of the IASLC international workshop on advances in pulmonary neuroendocrine tumors 2007 Journal of Thoracic Oncology 2008 3 10 1194 1201
18. Rekhtman N., Neuroendocrine tumors of the lung: an update Archives of Pathology and Laboratory Medicine 2010 134 11 1628 1638
19. Asian D. L., Gulbahce H. E., Pambuccian S. E., Manivel J. C., Jessurun J., Ki-67 immunoreactivity in the differential diagnosis of pulmonary neuroendocrine neoplasms in specimens with extensive crush artifact American Journal of Clinical Pathology 2005 123 6 874 878 (Pubitemid 40740685)
20. Du E. Z., Goldstraw P., Zacharias J., Tiffet O., Craig P. J., Nicholson A. G., Weidner N., Yi E. S., TTF-1 expression is specific for lung primary in typical and atypical carcinoids: TTF-1-positive carcinoids are predominantly in peripheral location Human Pathology 2004 35 7 825 831 (Pubitemid 38903075)
21. Kaufmann O., Dietel M., Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites Histopathology 2000 36 5 415 420 (Pubitemid 30311623)
22. El-Deiry W. S., Review: the p53 pathway and cancer therapy The Cancer Journal 1998 11 229 236 (Pubitemid 28508908)
23. Tsao M. S., Aviel-Ronen S., Ding K., Lau D., Liu N., Sakurada A., Whitehead M., Zhu C. Q., Livingston R., Johnson D. H., Rigas J., Seymour L., Winton T., Shepherd F. A., Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non-small-cell lung cancer Journal of Clinical Oncology 2007 25 33 5240 5247 (Pubitemid 350232256)
24. Miki M., Ball D. W., Linnoila R. I., Insights into the achaete-scute homolog-1 gene (hASH1) in normal and neoplastic human lung Lung Cancer 2012 75 1 58 65
25. Coate L. E., John T., Tsao M. S., Shepherd F. A., Molecular predictive and prognostic markers in non-small-cell lung cancer The Lancet Oncology 2009 10 10 1001 1010
26. Hirsch F. R., Varella-Garcia M., Bunn P. A. Jr., Di Maria M. V., Veve R., Bremnes R. M., Barn A. E., Zeng C., Franklin W. A., Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis Journal of Clinical Oncology 2003 21 20 3798 3807 (Pubitemid 46606235)
27. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., Majem M., Lopez-Vivanco G., Isla D., Provencio M., Insa A., Massuti B., Gonzalez-Larriba J. L., Paz-Ares L., Bover I., Garcia-Campelo R., Moreno M. A., Catot S., Rolfo C., Reguart N., Palmero R., Snchez J. M., Bastus R., Mayo C., Bertran-Alamillo J., Molina M. A., Sanchez J. J., Taron M., Screening for epidermal growth factor receptor mutations in lung cancer New England Journal of Medicine 2009 361 10 958 967
28. Mok T. S., Wu Y. L., Thongprasert S., Yang C. H., Chu D. T., Saijo N., Sunpaweravong P., Han B., Margono B., Ichinose Y., Nishiwaki Y., Ohe Y., Yang J. J., Chewaskulyong B., Jiang H., Duffield E. L., Watkins C. L., Armour A. A., Fukuoka M., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma New England Journal of Medicine 2009 361 10 947 957
29. Bunn P. A., Dziadziuszko R., Varella-Garcia M., Franklin W. A., Witta S. E., Kelly K., Hirsch F. R., Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy Clinical Cancer Research 2006 12 12 3652 3656 (Pubitemid 44000246)
30. Jackman D. M., Miller V. A., Cioffredi L. A., Yeap B. Y., Jnne P. A., Riely G. J., Ruiz M. G., Giaccone G., Sequist L. V., Johnson B. E., Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials Clinical Cancer Research 2009 15 16 5267 5273
31. Riely G. J., Politi K. A., Miller V. A., Pao W., Update on epidermal growth factor receptor mutations in non-small cell lung cancer Clinical Cancer Research 2006 12 24 7232 7241 (Pubitemid 46095394)
32. John T., Liu G., Tsao M. S., Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors Oncogene 2009 28 supplement 1 S14 S23
33. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I. I., Fong K. M., Lee H., Toyooka S., Shimizu N., Fujisawa T., Feng Z., Roth J. A., Herz J., Minna J. D., Gazdar A. F., Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers Journal of the National Cancer Institute 2005 97 5 339 346 (Pubitemid 40425952)
34. Yu J., Kane S., Wu J., Benedettini E., Li D., Reeves C., Innocenti G., Wetzel R., Crosby K., Becker A., Ferrante M., Wan C. C., Hong X., Chirieac L. R., Sholl L. M., Haack H., Smith B. L., Polakiewicz R. D., Tan Y., Gu T. L., Loda M., Zhou X., Comb M. J., Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer Clinical Cancer Research 2009 15 9 3023 3028
35. Ahrendt S. A., Anthony Decker P., Alawi E. A., Zhu Y. R., Sanchez-Cespedes M., Yang S. C., Haasler G. B., Kajdacsy-Balla A., Demeure M. J., Sidransky D., Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung Cancer 2001 92 6 1525 1530 (Pubitemid 32947838)
36. Mascaux C., Iannino N., Martin B., Paesmans M., Berghmans T., Dusart M., Haller A., Lothaire P., Meert A. P., Noel S., Lafitte J. J., Sculier J. P., The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis British Journal of Cancer 2005 92 1 131 139 (Pubitemid 40188446)
37. Suda K., Tomizawa K., Mitsudomi T., Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation Cancer and Metastasis Reviews 2010 29 1 49 60
38. Jackman D. M., Miller V. A., Cioffredi L. A., Yeap B. Y., Jnne P. A., Riely G. J., Ruiz M. G., Giaccone G., Sequist L. V., Johnson B. E., Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials Clinical Cancer Research 2009 15 16 5267 5273
39. Sakurada A., Tsao M. S., Predictive biomarkers for EGFR therapy IDrugs 2009 12 1 34 38
40. Mossé Y. P., Wood A., Maris J. M., Inhibition of ALK signaling for cancer therapy Clinical Cancer Research 2009 15 18 5609 5614
41. Soda M., Choi Y. L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S. I., Watanabe H., Kurashina K., Hatanaka H., Bando M., Ohno S., Ishikawa Y., Aburatani H., Niki T., Sohara Y., Sugiyama Y., Mano H., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 2007 448 7153 561 566 (Pubitemid 47206930)
42. Soda M., Takada S., Takeuchi K., Young L. C., Enomoto M., Ueno T., Haruta H., Hamada T., Yamashita Y., Ishikawa Y., Sugiyama Y., Mano H., A mouse model for EML4-ALK-positive lung cancer Proceedings of the National Academy of Sciences of the United States of America 2008 105 50 19893 19897
43. Kwak E. L., Bang Y. J., Camidge D. R., Shaw A. T., Solomon B., Maki R. G., Ou S. H. I., Dezube B. J., Jnne P. A., Costa D. B., Varella-Garcia M., Kim W. H., Lynch T. J., Fidias P., Stubbs H., Engelman J. A., Sequist L. V., Tan W., Gandhi L., Mino-Kenudson M., Wei G. C., Shreeve S. M., Ratain M. J., Settleman J., Christensen J. G., Haber D. A., Wilner K., Salgia R., Shapiro G. I., Clark J. W., Iafrate A. J., Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer New England Journal of Medicine 2010 363 18 1693 1703
44. Solomon B., Varella-Garcia M., Camidge D. R., ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer Journal of Thoracic Oncology 2009 4 12 1450 1454
45. Rodig S. J., Mino-Kenudson M., Dacic S., Yeap B. Y., Shaw A., Barletta J. A., Stubbs H., Law K., Lindeman N., Mark E., Janne P. A., Lynch T., Johnson B. E., Iafrate A. J., Chirieac L. R., Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population Clinical Cancer Research 2009 15 16 5216 5223
46. Shaw A. T., Yeap B. Y., Mino-Kenudson M., Digumarthy S. R., Costa D. B., Heist R. S., Solomon B., Stubbs H., Admane S., McDermott U., Settleman J., Kobayashi S., Mark E. J., Rodig S. J., Chirieac L. R., Kwak E. L., Lynch T. J., Iafrate A. J., Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK Journal of Clinical Oncology 2009 27 26 4247 4253
47. Sasaki T., Rodig S. J., Chirieac L. R., Jnne P. A., The biology and treatment of EML4-ALK non-small cell lung cancer European Journal of Cancer 2010 46 10 1773 1780
48. Mino-Kenudson M., Chirieac L. R., Law K., Hornick J. L., Lindeman N., Mark E. J., Cohen D. W., Johnson B. E., Jnne P. A., Iafrate A. J., Rodig S. J., A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry Clinical Cancer Research 2010 16 5 1561 1571
49. Cooper W. A., O'toole S., Boyer M., Horvath L., Mahar A., What's new in non-small cell lung cancer forpathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements Pathology 2011 43 2 103 115
50. Christensen J. G., Burrows J., Salgia R., c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention Cancer Letters 2005 225 1 1 26 (Pubitemid 40732764)
51. Kim E. S., Salgia R., MET pathway as a therapeutic target Journal of Thoracic Oncology 2009 4 4 444 447
52. Cappuzzo F., Marchetti A., Skokan M., Rossi E., Gajapathy S., Felicioni L., Grammastro M. D., Sciarrotta M. G., Buttitta F., Incarbone M., Toschi L., Finocchiaro G., Destro A., Terracciano L., Roncalli M., Alloisio M., Santoro A., Varella-Garcia M., Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients Journal of Clinical Oncology 2009 27 10 1667 1674
53. Engelman J. A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Joon O. P., Lindeman N., Gale C. M., Zhao X., Christensen J., Kosaka T., Holmes A. J., Rogers A. M., Cappuzzo F., Mok T., Lee C., Johnson B. E., Cantley L. C., Jnne P. A., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 2007 316 5827 1039 1043 (Pubitemid 46799492)
54. Sequist L. V., Waltman B. A., Dias-Santagata D., Digumarthy S., Turke A. B., Fidias P., Bergethon K., Shaw A. T., Gettinger S., Cosper A. K., Akhavanfard S., Heist R. S., Temel J., Christensen J. G., Wain J. C., Lynch T. J., Vernovsky K., Mark E. J., Lanuti M., Iafrate A. J., Mino-Kenudson M., Engelman J. A., Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors Science Translational Medicine 2011 3 75
55. Kadara H., Behrens C., Yuan P., Solis L., Liu D., Gu X., Minna J. D., Lee J. J., Kim E., Hong W. -K., Wistuba I. I., Lotan R., A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis Clinical Cancer Research 2011 17 6 1490 1501
56. Chen H. Y., Yu S. L., Chen C. H., Chang G. C., Chen C. Y., Yuan A., Cheng C. L., Wang C. H., Terng H. J., Kao S. F., Chan W. K., Li H. N., Liu C. C., Singh S., Chen W. J., Chen J. J. W., Yang P. C., A five-gene signature and clinical outcome in non-small-cell lung cancer New England Journal of Medicine 2007 356 1 11 20 (Pubitemid 46041749)